Label: PROMETHAZINE HYDROCHLORIDE tablet

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated June 4, 2014

If you are a consumer or patient please visit this version.

  • PRINCIPAL DISPLAY PANEL

    NDC: 51655-112-10

    MFG: 68382-040-01

    Promethazine Hydrochloride 12.5 MG

    10 Tablets

    Rx Only

    Dosage: See package insert

    Store at 68 to 77 degrees F.

    Keep out of the reach of children.

    Each tablet contains: Promethazine Hydrochloride, USP...12.5mg

    Mfg: by Cadila Healthcare Ltd. India

    Dist. By: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534

    Repackaged by Northwind Pharmaceuticals, Indianapolis, IN 46256

    Lot#

    Exp. Date:

    Promethazine HCL 51655-112

  • Clinical Pharmacology

    Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of chlorpromazine) of dopamine antagonist properties.Promethazine is an H1 receptor blocking agent. In addition to its antihistaminic action, it provides clinically useful sedative and antiemetic effects.

    Promethazine is well absorbed from the gastrointestinal tract. Clinical effects are apparent within 20 minutes after oral administration and generally last four to six hours, although they may persist as long as 12 hours. Promethazine is metabolized by the liver to a variety of compounds; the sulfoxides of promethazine and N-demethylpromethazine are the predominant metabolites appearing in the urine.

  • Indications and usage

    Promethazine Hydrochloride, is useful orally for Perennial and seasonal allergic rhinitis.

    Vasomotor rhinitis.

    Allergic conjunctivitis due to inhalant allergens and foods.

    Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.

    Amelioration of allergic reactions to blood or plasma.

    Dermographism.

    Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled.

    Preoperative, postoperative, or obstetric sedation.

    Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery.

    Therapy adjunctive to meperidine or other analgesics for control of post-operative pain.

    Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused.

    Active and prophylactic treatment of motion sickness.

    Antiemetic therapy in postoperative patients.

  • Contraindications

    Promethazine hydrochloride tablets, USP are contraindicated for use in pediatric patients less than two years of age.Promethazine hydrochloride tablets, USP are contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines.

    Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms including asthma

  • Drug Interactions

    CNS Depressants - Promethazine hydrochloride tablets, USP may increase, prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine hydrochloride. When given concomitantly with promethazine hydrochloride tablets, USP the dose of barbiturates should be reduced by at least one-half, and the dose of narcotics should be reduced by one-quarter to one-half. Dosage must be individualized. Excessive amounts of promethazine hydrochloride relative to a narcotic may lead to restlessness and motor hyperactivity in the patient with pain; these symptoms usually disappear with adequate control of the pain.Epinephrine - Because of the potential for promethazine hydrochloride to reverse epinephrine's vasopressor effect, epinephrine should NOT be used to treat hypotension associated with promethazine hydrochloride tablets, USP overdose.

    Anticholinergics - Concomitant use of other agents with anticholinergic properties should be undertaken with caution.

    Monoamine Oxidase Inhibitors (MAOI) - Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. This possibility should be considered with promethazine hydrochloride tablets, USP.

  • INGREDIENTS AND APPEARANCE
    PROMETHAZINE HYDROCHLORIDE 
    promethazine hydrochloride tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51655-112(NDC:68382-040)
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PROMETHAZINE HYDROCHLORIDE (UNII: R61ZEH7I1I) (PROMETHAZINE - UNII:FF28EJQ494) PROMETHAZINE HYDROCHLORIDE12.5 mg
    Product Characteristics
    ColorwhiteScore2 pieces
    ShapeROUNDSize6mm
    FlavorImprint Code ZC;01
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:51655-112-1010 in 1 BOTTLE, DISPENSING
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA04059603/03/2014
    Labeler - Northwind Pharmaceuticals (036986393)
    Registrant - Northwind Pharmaceuticals (036986393)
    Establishment
    NameAddressID/FEIBusiness Operations
    Northwind Pharmaceuticals036986393repack(51655-112)